tements within the meaning of the United States Private Securities Litigation Reform Act of 1995 (the "PSLRA") and that may be based on or include assumptions concerning the operations, future results and prospects of the Company. Such statements may be identified by the use of words like "plan," "expect," "aim," "believe," "project," "anticipate," "commit," "intend," "estimate," "will," "should," "could," "potential" and other expressions that indicate future events and trends.
All statements that address expectations or projections about the future, including without limitation, statements about product development, product launches, regulatory approvals, governmental and regulatory actions and proceedings, market position, acquisitions, sale of assets, revenues, expenditures, resumption of manufacturing and distribution of products and the impact of the recall and suspension of shipments on revenues, and other financial results, are forward-looking statements.
All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the PSLRA's "safe harbor" provisions, the Company provides the following cautionary statements identifying important economic, competitive, political, regulatory and technological factors, among others, that could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.
Such factors include (but are not limited to) the following:
- the ability to continue as a going concern;
- the consent decree between the Company and the U.S. Food and Drug Administration (the "FDA") and the Company's suspension of the production and shipment of all of the products that the Company manufactures and the related nationwide recall affecting all of the products that the Company manufactures, as well as the related material adverse effect on the Company's revenue, asset
Page: 1 2 3 4 5 6 Related medicine technology :1
|SOURCE KV Pharmaceutical Company|
Copyright©2009 PR Newswire.
All rights reserved
. ReSearch Pharmaceutical Services, Inc. Unaudited Quarterly Report for the Period Ended September 30, 20092
. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th3
. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results4
. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months5
. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results6
. Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media7
. Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results8
. Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results9
. Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference10
. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA11
. Endo Pharmaceuticals and LecTec Settle Patent Dispute